GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+2.72%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$499M
AUM Growth
+$499M
(-1.3%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
53.36%
Holding
52
New
8
Increased
14
Reduced
11
Closed
14
Top Buys
| 1 |
Zura Bio
ZURA
|
$27M |
| 2 |
Sarepta Therapeutics
SRPT
|
$14.2M |
| 3 |
Alkermes
ALKS
|
$12.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$11.1M |
| 5 |
Aclaris Therapeutics
ACRS
|
$7.78M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$21.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$16.9M |
| 3 |
Travere Therapeutics
TVTX
|
$14.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$12.6M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$11.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
4D Molecular Therapeutics
FDMT
$302M
| $6.32M | 1.24% |
+350,000
| New | +$6.32M |
|
27
Generation Bio
GBIO
$40.3M
| $5.62M | 1.1% |
1,022,537
| – | – |
|
28
Heron Therapeutics
HRTX
$204M
| $5.5M | 1.08% |
4,737,368
-1,080,000
| -19% | -$1.25M |
|
29
Acumen Pharmaceuticals
ABOS
$84.2M
| $5.06M | 0.99% |
1,051,267
| – | – |
|
|
IGMS
30
DELISTED
IGM Biosciences
IGMS
| $4.62M | 0.9% |
+500,000
| New | +$4.62M |
|
31
Seres Therapeutics
MCRB
$162M
| $4.49M | 0.88% |
+938,067
| New | +$4.49M |
|
32
Precision BioSciences
DTIL
$59.5M
| $3.93M | 0.77% |
7,469,736
-630,063
| -8% | -$331K |
|
33
Solid Biosciences
SLDB
$448M
| $3.06M | 0.6% |
584,458
+374,053
| +178% | +$1.96M |
|
34
Tourmaline Bio
TRML
$645M
| $2.02M | 0.4% |
+666,033
| New | +$2.02M |
|
35
Arcellx
ACLX
$3.95B
| $1.19M | 0.23% |
37,500
-219,506
| -85% | -$6.94M |
|
|
36
Travere Therapeutics
TVTX
$1.75B
| $922K | 0.18% |
60,000
-943,000
| -94% | -$14.5M |
|
37
Zevra Therapeutics
ZVRA
$501M
| – | – |
-347,824
| Closed | -$1.91M |
|
38
UroGen Pharma
URGN
$896M
| – | – |
-39,222
| Closed | -$362K |
|
39
Relay Therapeutics
RLAY
$709M
| – | – |
-658,127
| Closed | -$10.8M |
|
40
Praxis Precision Medicines
PRAX
$980M
| – | – |
-2,032,550
| Closed | -$1.64M |
|
41
Mersana Therapeutics
MRSN
$34.8M
| – | – |
0
| – | – |
|
42
MoonLake Immunotherapeutics
MLTX
$3.78B
| – | – |
-278,334
| Closed | -$5.95M |
|
43
Larimar Therapeutics
LRMR
$337M
| – | – |
-900,000
| Closed | -$4.08M |
|
|
44
KalVista Pharmaceuticals
KALV
$713M
| – | – |
-1,600,545
| Closed | -$12.6M |
|
|
45
Jazz Pharmaceuticals
JAZZ
$7.99B
| – | – |
-149,500
| Closed | -$21.9M |
|
46
89bio
ETNB
$1.37B
| – | – |
-250,000
| Closed | -$3.81M |
|
47
Day One Biopharmaceuticals
DAWN
$766M
| – | – |
-141,526
| Closed | -$1.89M |
|
48
Avalo Therapeutics
AVTX
$139M
| – | – |
-474,639
| Closed | -$831K |
|
49
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
0
| – | – |
|
|
ISEE
50
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-694,009
| Closed | -$16.9M |
|